Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 10/20 | 0.54 |
| ▸ | JAK3 | P52333 | 6/20 | 0.47 |
| ▸ | JAK2 | O60674 | 6/20 | 0.47 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.47 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 4/20 | 0.46 |
| ▸ | TYK2 | P29597 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | STK10 | O94804 | 1/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FER | P16591 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2568696 | 0.96 | NTRK1 (0.52) | NTRK1JAK3JAK2LIMK1LIMK2 | |
| SCHEMBL27872740 | 0.88 | NTRK1 (0.56) | NTRK1JAK3CCNT1CDK9CDK2 | |
| SCHEMBL3136120 | 0.88 | NTRK1 (0.56) | NTRK1JAK3CCNT1CDK9CDK2 | |
| SCHEMBL2569980 | 0.85 | NTRK1 (0.73) | NTRK1JAK3JAK2 | |
| SCHEMBL27872721 | 0.85 | NTRK1 (0.73) | NTRK1JAK3JAK2 | |
| SCHEMBL3137662 | 0.85 | NTRK1 (0.50) | NTRK1JAK3JAK2LIMK1LIMK2 | |
| SCHEMBL3137642 | 0.85 | NTRK1 (0.50) | NTRK1JAK3JAK2LIMK1LIMK2 | |
| SCHEMBL2566973 | 0.84 | NTRK1 (0.50) | NTRK1JAK3JAK2LIMK1LIMK2 | |
| SCHEMBL4696346 | 0.83 | JAK2 (0.50) | NTRK1JAK3JAK2LIMK1LIMK2 | |
| SCHEMBL4696343 | 0.83 | JAK2 (0.50) | NTRK1JAK3JAK2LIMK1LIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2383268-B1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2015-09-02 | — | — | EP | disclosed |
| EP-2383268-A1 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | AstraZeneca AB (SE) | 2011-11-02 | — | — | EP | disclosed |
| EP-1853602-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-07-14 | — | — | EP | disclosed |
| US-20080108669-A1 | Use 541 | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108669-A1 | Use 541 | TRPV1, P2RX3, P2RX5 | NTRK1 3837/4885JAK3 2868/4885JAK2 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.